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Splicing requires reversible phosphorylation of
serine/arginine-rich (SR) proteins, which direct splice
site selection in eukaryotic mRNA. These phosphory-
lation events are dependent on SR protein (SRPK) and
cdc2-like kinase (CLK) families. SRPK1 phosphoryla-
tion of splicing factors is restricted by a specific
docking interaction whereas CLK activity is less
constrained. To understand functional differences
between splicing factor targeting kinases, we deter-
mined crystal structures of CLK1 and CLK3. Intrigu-
ingly, in CLKs the SRPK1 docking site is blocked by
insertion of a previously unseen helix aH. In addition,
substrate docking grooves present in related mitogen
activating protein kinases (MAPKs) are inaccessible
due to a CLK specific b7/8-hairpin insert. Thus, the
unconstrained substrate interaction together with
the determined active-site mediated substrate
specificity allows CLKs to complete the functionally
important hyperphosphorylation of splicing factors
like ASF/SF2. In addition, despite high sequence
conservation, we identified inhibitors with surprising
isoform specificity for CLK1 over CLK3.
INTRODUCTION
Cdc2-like kinases (CLK) are conserved throughout eukaryote
evolution, from Saccharomyces cerevisiae (KNS1), Arabidopsis
thaliana (AFC1-3), and Drosophila melanogaster (DOA) to mouse
(CLK/STY) and human (CLK1-4) (Yun et al., 1994). Based on an
unique and conserved ‘‘EHLAMMERILG’’ signature motif,
CLKs are also often referred to as ‘‘LAMMER kinases.’’ The
conserved signature motif of CLKs has been suggested to
dictate CLK substrate specificity (Yun et al., 1994). Interestingly,
CLKs are dual-specificity kinases, which have the ability to auto-
phosphorylate at tyrosine residues but phosphorylate their
substrates exclusively on serine/threonine residues (Nayler
et al., 1997).
Consequences of CLK dysfunction are dramatically illustrated
in Drosophila by defects in the CLK homolog DOA (darkener of352 Structure 17, 352–362, March 11, 2009 ª2009 Elsevier Ltd All riapricot). Mutations in the doa locus affect sexual differentiation
by specifically disrupting sex-specific splicing of doublesex (dsx)
pre-mRNA through interaction with the transformer splicing
regulatory proteins TRA and TRA2 (Du et al., 1998). The doa
gene has an essential role in Drosophila embryogenesis; it is ex-
pressed throughout development and its mutation leads to
defects in segmentation, eye formation, and neuronal develop-
ment (Yun et al., 1994). In humans, splicing of the homolog
hTRA2beta is regulated by CLK2 (Stoilov et al., 2004) whereas
CLK1 plays an important role in neuronal differentiation (Myers
et al., 1994). CLK3 is abundantly expressed in mature sperma-
tozoa and might play a role in the fertilization process (Menegay
et al., 1999).
Alternative splicing is controlled by phosphorylation of serine/
arginine-rich (SR) splicing factors, which have been identified as
CLK interaction partners and substrates (Colwill et al., 1996a,
1996b; Duncan et al., 1997). Splicing is an important regulatory
mechanism in eukaryotes that allows a single gene to generate
multiple protein isoforms with distinct function. Indeed, some
35%–60% of human genes encode at least two alternatively
spliced isoforms (Modrek and Lee, 2002), and deregulation of
splicing is frequently linked to hereditary diseases (Faustino
and Cooper, 2003).
The prototypical SR protein ASF/SF2 contains two RS
(arginine/serine) repeat domains with multiple arginine-serine
dipeptides. Phosphorylation of the first RS domain (RS1) trig-
gers nuclear import and accumulation in nuclear speckles (Ma
et al., 2008; Velazquez-Dones et al., 2005). This phosphorylation
event is controlled by SR-protein kinase SRPK. Subsequent
phosphorylation of the RS2 domain by CLK dissolves these
nuclear speckles and releases ASF/SF2 for splicing and
dephosphorylation (Colwill et al., 1996b; Duncan et al., 1998).
Selectivity for the RS1 domain of SRPK kinases can be rational-
ized by the crystal structure of the SRPK1-ASF/SF2 complex
(Ngo et al., 2008). The first RS repeat is bound to an acidic dock-
ing groove within the kinase C-lobe formed by helix aG and
a helical insert typically found in MAPKs. A self-primed phos-
phoserine from the C0 end of RS1 is also observed close to
the active site at a probable P+2 site. Biochemical experiments
have suggested that the entire RS1 domain is threaded in the C0
to N0 direction with the successive phosphorylation of each RS
dipeptide driving their transfer to the basic P+2 pocket. Docking
to the RS2 domain, however, mighty be disfavored by the pres-
ence of shorter interrupted stretches of RS dipeptides. CLKghts reserved
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Structural Insertions Define CLK Kinase Activityactivity is not restricted to RS repeats, and these kinases might
have more diverse substrates in splicing control (Colwill et al.,
1996a).
In analogy with SRPK1, it has been suggested that the
LAMMER motif forms a conserved docking site for CLK
substrates. To assess this hypothesis and rationalize the distinct
activities of the SRPK and CLK kinases regulating splicing, we
determined the crystal structures of the human CLK1 and CLK3
kinase domains. Our structural analysis revealed that despite
a similar MAPK insert and an aG helix comprising the LAMMER
motif, the restrictive docking sites of both the SRPK and MAPKs
are disrupted in the CLK family by two previously unseen inser-
tions. We determined the substrate specificity of CLK1 and
compared the two CLK isoforms with respect to their binding
profiles versus a large panel of established kinase inhibitors.
The identified chemical scaffolds and the presented high-resolu-
tion structure of CLK1 in complex with the ATP mimetic inhibitor
hymenialdisine provide the basis for further structure-based
inhibitor development and validation of the functional roles of
CLK kinases in vivo.
RESULTS
Overview of the CLK1 and CLK3 Structures
The kinase domains of CLK1 and CLK3 were expressed in E. coli
in active form as demonstrated by extensive autophosphoryla-
Table 1. Structural Refinement and Data Collection
CLK1 CLK3
Data Collection
PDB code 1Z57 2EU9
Ligand Debromohymenialdisine None
Space group C2 C2
Cell dimensions [A˚] a = 92.27, b = 64.43,
c = 80.12
a = 108.72, b = 45.06,
c = 84.01
a, b, g b = 119.19 b = 115.23
Resolution [A˚] 1.7 1.53
Unique observations 45196 55697
Completenessa [%] 95 (82) 99.8 (94)
Redundancya 5.26 (1.77)
Rmerge
a 0.095 (0.25) 0.057 (0.37)
Refinement
Resolution [A˚] 60-1.7 60-1.53
Rwork / Rfree [%] 14.0 / 18.6 20.1 / 17.1
Atoms (P/L/W/)b 2692/ 18 /401 2848/ 0/ 347
B-factors
(P/L/W/)b [A˚2]
21.3/ 13.9 /34 19.6/ — /29.1
Rmsd bonds [A˚] 0.015 0.019
Rmsd angles [] 1.591 1.743
Ramachandran
Favored [%] 98.3 99.7
Allowed [%] 1.3 0.0
Disallowed 0.3 0.3
a Values in parentheses correspond to the highest resolution shell.
b (P/L/W) represents protein/ligand/water.Structure 17, 3tion. Both recombinant proteins required optimization of buffer
conditions for crystallization studies (see Experimental Proce-
dures) and phosphatase treatment to obtain homogeneous
sample. High-resolution crystal structures were solved for
CLK1 in complex with the kinase inhibitor hymenialdisine and
for the apo-CLK3 kinase domain (see Table 1 for crystallization
and refinement statistics). Both structures were well defined by
the electron density except for two short loop regions in CLK1
(residues 307–310 and 483–484) and three regions in CLK3
(residues 127–135, 304, and 482–484) that were not modeled.
The catalytic domains of CLK1 and CLK3 display the typical
protein kinase fold as shown in Figure 1. The N-terminal lobe
consists of three b strands (b1–b3) followed by an a helix (aC)
and two further b strands (b4 and b5). The C-terminal lobe
exhibits several unique features that define the CLK family. The
highly conserved signature motif of this group (EHLAMMERILG,
residues 386–396 in CLK1 and 381–391 in CLK3), from which the
family name LAMMER-kinases is derived, forms part of helix aG
located at the bottom of the C-terminal lobe (Figure 1A) and is
made solvent-inaccessible by a large insertion between residues
400 and 432 in CLK1 and 395 and 427 in CLK3. This region
displays a high similarity to the typical helix-loop-helix insertion
motif found at the same site in the MAPK family. However, in
the CLK structures, the second helix is replaced by a small
two-strand b sheet (formed by residues 409–418 in CLK1 and
404–413 in CLK3). This motif is followed by helix aH that is
unique to these CLK structures (residues 424–432 and 419–
427 in CLK1 and CLK3, respectively). A second unique insertion
conserved in the CLK family is present at the top of the
C-terminal lobe where residues 300–317 in CLK1 and 295–312
in CLK3 form an extended b-hairpin (bhp-bhp0).
Structural Differences between CLK1 and CLK3
Superposition of all main chain atoms of CLK1 and CLK3 reveals
high structural similarity between the two proteins (Figure 1B).
The main structural difference is a change in the relative orienta-
tion of the N- and C-terminal lobes such that CLK3 exhibits
a more open conformation than CLK1. This change is reflected
in the root-mean-square deviation (rmsd) values, which are
1.72 A˚ for all main chain atoms but just 0.98 A˚ and 0.97 A˚ for
the individual N- and C-terminal lobes, respectively. The differ-
ence in lobe orientation is likely to be an effect of the inhibitor
bound to CLK1 mimicking binding of the ATP cofactor. As high-
lighted in Figure 1B, the most divergent regions are the MAPK-
like insertion, helix aG, and the partially disordered tips of the
bhp-bhp0 hairpin insertion. CLK3 also shows additional
secondary structure elements at the N and C termini not
observed in CLK1: first, a short hairpin comprising residues
136–145 that folds above the N-terminal domain; and second,
an additional helical segment at the C terminus formed by resi-
dues 476–481. Within the CLK family, CLK1 and CLK3 are the
most distantly related with respect to a sequence alignment (Fig-
ure 1C; see Figure S1 available online). Both proteins share only
48.4% sequence identity. However, many of the surface
residues that are conserved throughout the CLK family are the
same in CLK1 and CLK3 (Figure 1D).
Active Conformation of the Catalytic Domain
The unphosphorylated CLK catalytic domains are in an active
conformation as indicated by a closed conformation of both52–362, March 11, 2009 ª2009 Elsevier Ltd All rights reserved 353
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Structural Insertions Define CLK Kinase Activitykinase lobes and well-ordered activation segments (Figure 2). In
both domains, helix aC is positioned in close proximity to the
ATP binding site with the characteristic salt bridge between the
conserved aC glutamate (CLK1, Glu206) and the active site
lysine (Lys191). The activation loop (A loop) of both kinases is
well defined in the electron density and adopts the characteristic
conformation of active kinases despite the absence of a phos-
Figure 1. Overview of the CLK1 and CLK3
Structures
(A) Structure of the CLK1 kinase domain. Specific
structural insertions defining the LAMMER kinases
are highlighted by different colors and are labeled.
The inhibitor debromohymenialdisine is shown in
stick representation.
(B) Structural superimposition of the nonphos-
phorylated CLK1 (red) and CLK3 structures (blue).
(C) Sequence identity among the members of the
human CLK family.
(D) Surface residue conservation mapped onto the
CLK1 structure. Residues conserved among all
CLK family members are shown in red, conserved
hydrophobic residues in yellow, conserved polar
residues in green and regions of diversity are
shown in gray. A sequence alignment is shown in
Supplemental Data.
Figure 2. CLK Activation Segments
(A) Superimposition of the activation segments of CLK1 (red) and CLK3 (green) as well as of SRPK1 (magenta) (PDB code 1WBP). The functional elements of the
segment (DFG, A loop and P1 loop) as well as the catalytic loop and the helix aC are labeled.
(B) Activation segment of CLK1. The activation segment is shown in blue, the catalytic loop in green, and aC in red. Selected residues within these structural
elements are labeled in corresponding colors.
phorylation. Its conformation is similar in
both CLK structures, mainly constrained
by a short antiparallel b sheet formed
between b6 and b9 and a conserved
hydrogen bond between His336 and
Glu334 in CLK1. A similar A loop confor-
mation is also found in SRPK1 (Ngo
et al., 2005). Both CLK activation seg-
ments have a very acidic A loop stabilized
by polar contacts. An additional hydrogen bond is formed in
CLK1 between the A loop residue Tyr331 and His212 in aC.
This interaction, however, is not conserved: in CLK3 it is re-
placed by a hydrophobic contact between the Tyr331-equivalent
Phe326 and the aC residues Val204 and Lys207. The catalytic
loop motif HRD is replaced by a HTD motif among all members
of the CLK family and in SRPK1.354 Structure 17, 352–362, March 11, 2009 ª2009 Elsevier Ltd All rights reserved
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(A) Overview showing the location of the b-hairpin insert conserved within the CLK family. The hairpin interacts with a groove formed by helix aD and aE. Shown is
the CLK1 b-hairpin (bhp and bhp0) in yellow and the CLK3 b-hairpin in blue. A docking peptide of the MAPK p38 (PDB code 1LEW) is shown in ball-and-stick
representation (Chang et al., 2002). A detailed view of the hydrophobic interaction formed by Leu316 conserved within the CLK family (CLK3 is shown in
blue). Leu316 superimposes well with a leucine present at this position in the MEF2A-derived MAPK docking peptide (colored in white). A Sequence alignment
of human CLK family b-hairpin inserts is shown under the peptide interaction insert. Conserved residues are highlighted in red, the conserved hydrophobic
residues making contact with the binding groove are highlighted in yellow and marked by an asterisk. The disordered tip of the hairpin insert is shown by a dotted
yellow line.
(B) Interactions formed by CLK1 b-hairpin residues with the surface of CLK1. Residues present in the hairpin are labeled in dark blue and those present in the
kinase lower lobe are labeled in red.Unique LAMMER Kinase Insertions
The most striking feature of the CLK C-terminal lobe is a long
insertion between the two sheets b7 and b8. This insert forms
the CLK-specific bhp-bhp0 hairpin that folds over a shallowStructure 17, 3groove created by the helices aD and aE (Figure 3). Interestingly,
substrates of MAPKs recognize the same shallow groove
through so-called D motif docking sites by using mainly hydro-
phobic contacts. Although MAPK docking peptides bind in an52–362, March 11, 2009 ª2009 Elsevier Ltd All rights reserved 355
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Structural Insertions Define CLK Kinase ActivityFigure 4. Docking Grooves and Determinants of Substrate Binding of CLK1 and SRPK1
Shown is the surface of SRPK, the corresponding docking peptide and secondary structure elements for CLK1. The SRPK docking site is blocked by helix aH in
CLK family members. The docking site in SRPK is important for substrate recognition (Ngo et al., 2008). In this figure, CLK1 has been superimposed onto the
structure of SRPK1 in complex with a docking peptide derived from the yeast SR-like protein Npl3p (PDB code 1WBP; Ngo et al., 2005). The superimposition
showed that binding of a potential docking peptide is impaired due to the presence of helix aH in CLK family members. Inset shows SRPK1-docking peptide
alone.orientation that is rotated approximately 90 compared with the
b-hairpin, their central hydrophobic patch is mimicked by
a conserved hydrophobic residue in the b-hairpin (Figures 3A
and 3B). This b-hairpin structure is common to CLK1 and
CLK3. Although there is low sequence homology in the region,
a number of positions in the b-hairpin are conserved throughout
the CLK family (Figure 3C). Apart from the hydrophobic patch
(Leu316 in CLK1) and a conserved valine (Val297), the b-hairpin
is docked to the shallow groove by a number of hydrogen bonds,
including backbone contacts formed by the side chains of
Arg311 and Ser299 in CLK1. This hairpin is also the site of a struc-
turally uncharacterized insertion of 250 residues in SRPK1.
The crystal structure of SRPK1 revealed an unusual docking
groove in the C-terminal lobe (formed between helix aF and helix
aG) that is not present in the CLK structures, thus providing
a potential explanation for the restriction of SRPK1 activity
toward RS substrate regions. This site is located adjacent to
the MAPK-like insertion, which is present in both SRPK1 and
the CLKs. However, the structural equivalent of the docking
groove in SRPK1 is covered by the unique CLK helix aH
(Figure 4). Surprisingly, this helix also buries helix aG, which
comprises the highly conserved EHLAMMERILG signature motif
(Figure 4). On the basis of sequence alignments, it has been
suggested that this motif is solvent exposed and on the basis
of its extraordinary conservation the signature motif has been
predicted as an interaction site for either substrates or effectors
(Yun et al., 1994). However, in both CLK structures the LAMMER
motif is made solvent-inaccessible by aH and the adjacent356 Structure 17, 352–362, March 11, 2009 ª2009 Elsevier Ltd All rigMAPK-like insertion. Most notably, the alanine (uniquely replaced
by valine in CLK3) that lies at the center of helix aG is packed
against a strictly conserved tryptophan (CLK1, Trp419; CLK3,
Trp414) located between the aH and the MAPK-like inserts.
Determination of Substrate Specificity
Consistent with its active conformation, the catalytic domain of
CLK1 showed constitutive kinase activity against a degenerate
peptide array library. We determined the active site mediated
substrate specificity of CLK1 and compared its specificity with
previous data reported for CLK2 and CLK3 (Figure 5) (Hutti
et al., 2004; Miller et al., 2008). CLK1 showed an approximately
two-fold phosphorylation preference for serine over threonine
and no detectable phosphorylation of tyrosine residues. The
primary selectivity for CLK1 was for arginine in the position P-3
(3 residues N-terminal to the phosphorylation site), which was
also observed for CLK2 and CLK3. CLK1 also showed a strong
selection for proline at position P+1, whereas CLK2 and CLK3
were less selective at this position. Interestingly, CLK1 lacks
selectivity for arginine at position P+1 as seen for CLK2 and
CLK3 and that has also been noted in previous studies of
LAMMER kinases (including Drosophila DOA) (Nikolakaki et al.,
2002). A greater role for CLK3 as a SR-specific protein kinase
is also suggested by its stronger preference for arginine in P-1,
whereas CLK1 shows no preference at this position. Although
all CLK kinases disfavor large hydrophobic residues at P-2,
CLK1 showed a pronounced preference for glutamate at that
position.hts reserved
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Structural Insertions Define CLK Kinase ActivityFigure 5. Consensus Phosphorylation Motifs
(A) Biotinylated peptides bearing the indicated residue at the indicated position relative to a central Ser/Thr phosphoacceptor site were subjected to phosphor-
ylation by CLK1 using radiolabeled ATP. Aliquots of each reaction were subsequently spotted onto a streptavidin membrane, which was washed, dried, and
exposed to a phosphor screen.
(B) Model of a CLK1 consensus peptide complex. The consensus sequence was modeled into the CLK1 substrate binding site using the structure of the PKA
substrate complex as a template (PDB code 1JBP). CLK1 surface residues cited in the text are labeled in yellow and substrate positions are labeled in black.To rationalize the observed substrate specificity for CLK1, we
generated a docking model of a substrate complex using the
peptide cocrystal structure of PKA (Protein Data Bank [PDB]
code 1JBP) as a template (Figure 5B). The model explains the
main selectivities observed in the peptide array experiment. In
particular, the proline residue in P+1 fits in a small hydrophobic
surface pocket formed by hydrophobic regions of the Arg346
side chain. The strong preference for glutamate in P-2 can be
explained by a hydrogen bond interaction with His382, and the
selection for arginine in P-3 is likely to be due to formation of
a salt bridge with Asp250. Also, the preference for phenylalanineStructure 17, 3in position 5 can be explained by a deep hydrophobic surface
cavity. However, it is unlikely that the conserved CLK1 residues
Arg343/Arg346 select for a phosphorylated peptide in P+2 as
suggested for SRPK1 (Ngo et al., 2008). This basic pocket is
too distant from this substrate position and the side chain is
oriented away from this basic binding surface pocket.
ASF/SF2 Phosphorylation by CLK1
To further characterize the role of CLK1, we analyzed the activity
of the full-length protein against ASF/SF2. The additional
N-terminal domain in CLK1 is required for efficient ASF/SF252–362, March 11, 2009 ª2009 Elsevier Ltd All rights reserved 357
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multiple arginine-serine dipeptides. As a kinase-inactive mutant,
the full-length protein colocalizes with other splicing factors to
nuclear speckles, whereas wild-type CLK1 causes speckles to
dissolve (Colwill et al., 1996b; Duncan et al., 1998). According
to the current model, SRPK1 hypophosphorylates ASF/SF2
(generating pASF/SF2), which causes its targeting to nuclear
speckles. Subsequently pASF/SF2 becomes hyperphosphory-
lated by CLK1 and is released as ppASF/SF2. In our experiments,
SRPK1-treated ASF/SF2, which contains 12–14 phosphorylated
serines, was used as a control to monitor the extent of ASF/SF2
phosphorylation by CLK1. ASF/SF2 treated with CLK1 alone
produced two dominant phosphorylated species; the major
product migrated faster than pASF/SF2, indicating fewer than
12 phosphates, whereas the minor product, representing
ppASF/SF2 (hyperphosphorylated) migrated more slowly
(Figure 6A). However, treatment with both CLK1 and SRPK1
completes phosphorylation (Figure 6A). These results are consis-
tent with the nonoverlapping substrate specificity of the two
kinases and the loss of selection of CLK1 for the RS1 repeat.
Indeed, using glutathione S-transferase (GST) pull-down experi-
ments we observed binding of CLK1 to both unphosphorylated
protein and pASF/SF2, with the robust binding to pASF/SF2,
supporting the complementarity of the two kinases (Figure 6B).
Inhibitor Binding and Specificity
CLK1 was crystallized in the presence of hymenialdisine,
a marine sponge metabolite that has nanomolar activity against
CDKs, MEK1, GSK3b, and CK1 (Meijer et al., 2000). In the crystal
structure, hymenialdisine is bound in the typical ATP-mimetic
manner, at the hinge backbone region where residues Glu242,
Leu243, and Leu244 interact through one water-mediated and
two direct main-chain hydrogen bonds. In addition, further
hydrogen bonds are observed with conserved residues
Asp305, Lys191, and Asn294 resembling the well-conserved
binding mode of this inhibitor class (Figure 7A). No density was
observed for the bromide substituent, suggesting that the
halogen bond was hydrolyzed to yield debromohymenialdisine.
Figure 6. CLK1 and SRPK1 Show Nonover-
lapping Complementary Activity
(A) Coomassie-stained SDS-PAGE gel showing
that CLK1 efficiently converts pASF/SF2 into
ppASF/SF2.
(B) GST pull-down assay showing association of
CLK1 with ASF/SF2 and pASF/SF2.
Previous work identified the benzothia-
zole compound TG003 as a CLK1-
specific inhibitor in vitro with an IC50 of
20 nM (Muraki et al., 2004). Such inhibitors
provide interesting biological tools as well
as potential drugs. We used a facile
thermal stability shift assay to rapidly
screen a collection of several hundred
commercially available kinase inhibitors
including TG003. This method identifies
binding compounds by a shift in the
protein’s melting temperature, Tm. For
a large number of kinase inhibitors, these values have proven to
correlate highly with binding constants determined by direct
measurement (e.g., isothermal titration calorimetry) or with IC50
values such that larger Tm shifts are observed for higher affinity
inhibitors (Bullock et al., 2005). A recent systematic study of 60
protein kinases and over 150 validated kinase inhibitors indicated
that a 4C shift in thermal stability at an inhibitor concentration of
10 mM corresponds to a binding affinity below 1 mM whereas an
8C shift typically reflects a KD of 100 nM or less (Fedorov et al.,
2007). From our screening of CLK kinases, we selected 11
compounds with a Tm shift greater than 4
C for further analysis
of their kinase inhibitory activity at 100 nM concentration
(Figure 7). Overall, CLK1 appears more susceptible to inhibition
than CLK3. CLK1 showed less than 50% activity with 9 of the
11 inhibitors compared with just one with CLK3. This dual-spec-
ificity inhibitor, compound 11 (a well-characterized CDK1/2 inhib-
itor), was the most effective compound for both kinases, reducing
CLK1 activity to below 1%. Six CLK1 inhibitors were identified
with greater potency than TG003. However, five of these include
the more promiscuous staurosporine, BIM-9, hymenialdisine,
iodotubericidin, and the CDK1/2 inhibitor. The final inhibitor in
this group, compound 4, belongs to a novel class of imidazo[1,2-
b]pyridazines, which are more selective and currently being inves-
tigated as a promising inhibitor scaffold for the development of
antioncogenic PIM kinase inhibitors (Pogacic et al., 2007).
DISCUSSION
CLK and SRPK kinases mediate processive hyperphosphoryla-
tion of SR proteins that direct RNA splicing, but show distinct
binding activities and kinetics (Ma et al., 2008; Velazquez-Dones
et al., 2005). Understanding of SRPK activity has been advanced
by recent crystal structures of the SRPK1 kinase domain, which
revealed an unusual docking site restricting SRPK1 activity
toward the first RS repeat domain (RS1) of ASF/SF2. Here the
determined structures and substrate specificity of CLK1 provide
corroborative evidence to support the less constrained activity of
CLK kinases.358 Structure 17, 352–362, March 11, 2009 ª2009 Elsevier Ltd All rights reserved
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A B
Figure 7. Inhibitor Binding and Specificity
(A) Binding of debromohymenialdisine to CLK1. Electron density (2FoFc) for the inhibitor is shown in blue.
(B) Chart showing CLK1 and CLK3 kinase activities relative to the reference in the presence of 100 nM of 11 compounds causing the highest Tm shifts.
(C) Table of the inhibitor data with corresponding chemical structures.Both the SRPK and CLK kinases show a constitutively active
conformation and share a similar variation of the MAPK insert
that is a feature of the CMGC family. Most revealing, the docking
groove of SRPK is lost in the CLK1 and CLK3 structures due toStructure 17, 3the previously unseen insertion of helix aH. This buries the signa-
ture EHLAMMERILG motif of helix aG that defines the subfamily
of LAMMER kinases. Rather than forming the expected
substrate interaction site, this sequence conservation appears52–362, March 11, 2009 ª2009 Elsevier Ltd All rights reserved 359
Structure
Structural Insertions Define CLK Kinase Activityto reflect its important role within the structural core of the kinase
C-lobe. In addition, the typical MAPK docking site is also occu-
pied by the unusual bhp-bhp0 hairpin insertion, which forms
a similar hydrophobic patch with the kinase. The much larger
domain insertion present at the same site in SRPK1 is not
required for substrate interaction or catalysis, but is suggested
to stabilize the active conformation (Ngo et al., 2007).
SRPK kinases are known to be highly specific for RS repeat
substrates and to only phosphorylate serine (not threonine)
residues that are located adjacent to arginines (and not lysines)
(Gui et al., 1994; Wang et al., 1998). In contrast, CLK kinases
have unusual dual specificity with propensity to autophosphory-
late on serine, threonine, and tyrosine residues (Ben-David et al.,
1991; Howell et al., 1991). In our degenerate peptide substrate
arrays, the purified CLK activity was preferentially targeted
toward serine rather than threonine residues, but tyrosine
substrate phosphorylation was not observed. CLK1 behaved
as a typical CDK-like proline-directed kinase with strong selec-
tivity for serine phosphorylation sites with proline at position
P+1 and arginine at position P-3, whereas CLK2 and CLK3
showed intermediate specificity compared with SRPK1 (Miller
et al., 2008). These results correlate well with the substrate phos-
phorylation sites of CLK1 observed in vivo (Colwill et al., 1996b).
For example, CLK1 activates PTP1B by serine phosphorylation
within this motif (Moeslein et al., 1999). In ASF/SF2 the RS1
domain targeted by SRPK1 contains a segment of eight consec-
utive RS dipeptides, whereas the RS2 motif contains three SP
dipeptides that interrupt the RS repeat. Our data support that
CLK1 complements SRPK1 activity due to the preferential phos-
phorylation of this second motif. This is directed through (i)
absence of the restrictive docking groove; (ii) selection for proline
at position P+1; and (iii) colocalization to nuclear speckles
directed by the N-terminal RS domain of CLK1.
Dysregulation of alternative splicing is a common feature of
human cancers (Venables, 2004). ASF/SF2 is a newly identified
proto-oncogene, found to be upregulated in a variety of human
cancers; a slight overexpression of this protein is sufficient to
transform immortal rodent fibroblasts giving rise to sarcomas
in nude mice (Karni et al., 2007). The benzothiazole compound
TG003 was recently reported to inhibit ASF/SF2-dependent
splicing of b-globin pre-mRNA in vitro by suppression of CLK1-
mediated phosphorylation (Muraki et al., 2004). It also sup-
pressed CLK1-dependent alternative splicing in mammalian
cells and rescued the embryonic defects induced by excessive
CLK activity in Xenopus. Many other diseases are linked to
specific splicing changes. For example, aberrant CLK2 splicing
is associated with exon 10 inclusion in tau, which produces the
neurodegenerative fibrillar aggregates found in Alzheimer’s
disease (Glatz et al., 2006; Hartmann et al., 2001). The high-
resolution structure of CLK1 in complex with the kinase inhibitor
hymenialdisine provides a basis for further structure-based
inhibitor development. Such compounds will form valuable tools
to probe CLK function and therapeutic potential. Of particular
interest from our ligand screening is compound 4, a novel imi-
dazo[1,2-b]pyridazine that shows potency and selectivity
comparable with TG003.
Overall, the structures and substrate specificity profiles
provide a rationale for the distinct activities observed for the
CLK and SRPK kinase families. The CLK kinases show features360 Structure 17, 352–362, March 11, 2009 ª2009 Elsevier Ltd All riof both the MAPK and CDK family kinases such as proline-
directed activity (particularly for CLK1). Their structures reveal
that the LAMMER kinase family-specific insertions block known
interaction sites and, thus, promote target selection by the active
site to complement SRPK kinases. These data further our under-
standing of the interplay of these two kinase families in alternate
splicing and reveal possible intervention points for cancer
treatment.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification
The kinase domains of human CLK1 (residues: 148–484 [C terminus, gi:
4758008]) and CLK3 (residues 127–484, gi: 153791372 isoform B) were
subclonedby ligation independentcloning into a PET-derivedexpressionvector,
pLIC, and expression performed in BL21(DE3) with 1 mM IPTG induction for 4 hr
at 18C. These constructs were identified after expression screening nine
different N- and C-terminal truncation constructs for each kinase. Cells were
lysed using a high-pressure homogenizer, cleared by centrifugation, and the
lysates purified by Ni-NTA chromatography. The eluted proteins were treated
with lambda phosphatase together with TEV protease overnight to remove
phosphorylation and the hexahistidine tag, respectively. The proteins were
further purified by size exclusion chromatography using a S75 16/60 HiLoad
column. A fluorescence-based thermal stability shift assay (Vedadi et al.,
2006) was used to screen for optimal buffer conditions to prevent precipitation
above concentrations of 1 mg/ml. The midpoint of the unfolding transition, Tm,
was shifted by the addition of L-arginine/L-glutamic acid by more than 10C.
The preferred buffer, 50 mM HEPES (pH 7.5), 500 mM NaCl, 5% glycerol,
50 mM L-glutamic acid, 50 mM L-arginine, increased solubility and resulted
in monodisperse protein as judged by analytical ultracentrifugation. A final puri-
fication step using anion exchange chromatography with a MonoQ 5/50 GL
column was used to resolve nonphosphorylated CLK3. The correct protein
masses were confirmed by liquid chromatography electrospray ionization
mass spectrometry.
Determination of Peptide Phosphorylation Specificity
Phosphorylation motifs were determined by phosphorylation of a set of
201 peptide mixtures in multiwell plates essentially as described by Hutti
et al. (2004). Reactions contained 20 mM HEPES (pH 7.4), 10 mM MgCl2,
1 mM dithiothreitol (DTT), 0.1% Tween 20, 50 mM ATP (including 0.3 mCi/ml
g-[33P]-ATP), 50 mM peptide substrate, and 1 mM CLK1 kinase for 2 hr at 30C.
Peptide substrates had the general sequence YAXXXXX-S/T-XXXXAGKK
(biotin), where S/T is an equal mix of serine and threonine, and X represents
degenerate positions comprising 17 amino acids (excluding cysteine, serine
and threonine). Each of the 201 peptides in the set had 1 of the X positions
fixed as 1 of 22 residues (all unmodified amino acids, phosphothreonine, or
phosphotyrosine). To quantify the extent of phosphorylation of each peptide,
aliquots were spotted onto a streptavidin membrane, which was washed,
dried, and exposed to a phosphor screen as done previously (Hutti et al.,
2004).
Protein Stability Shift Assay
Thermal melting experiments were carried out using the Mx3005p real-time
polymerase chain reaction machine (Agilent) and employing a protein concen-
tration of 2 mM. The assay and data evaluation were carried out as described
elsewhere (Fedorov et al., 2007; Matulis et al., 2005; Niesen et al., 2007).
Imidazo-pyridazines were purchased from Biofocus (DPI), and all other inhib-
itors were purchased from Calbiochem.
Kinase Assay
Phosphorylation reactions were monitored using a coupled-enzyme assay in
which ADP production is coupled to NADH oxidation by pyruvate kinase
(PK) and lactate dehydrogenase. The assay was carried out in a total volume
of 200 ml in a buffer containing 50 mM HEPES (pH 7.5), 150 mM NaCl,
10 mM KCl, 2 mM DTT, 10 mM MgCl2, 1.0 mM phosphoenolpyruvate,
0.2 mM NADH, 15 U/ml pyruvate kinase, 30 U/ml lactate dehydrogenase,ghts reserved
Structure
Structural Insertions Define CLK Kinase Activityand 30 nM CLK1. The reaction was monitored at 340 nm at 25C on a Spectra-
max spectrophotometer (Molecular Devices, Sunnyvale, CA). The reaction
was started by addition of 0.1 mM ATP after a 10 min preincubation of the
reaction mixture at 25C. The CLK1 consensus peptide (AFRREWSPGKEAKK)
was used as substrate at a concentration of 100 mM. Inhibitors, dissolved in
dimethyl sulfoxide (DMSO), were added at the beginning of the pre-incubation
period resulting in a final DMSO concentration of 2% in the assay. Kinetic
analysis was performed by nonlinear regression fitting using the program
KaleidaGraph (Synergy Software, CA).
GST Pull-Down Assay
The phosphorylation of His-ASF/SF2 by SRPK1, CLK1, or both was performed
in 20 mM Tris-HCl (pH 7.5), 75 mM NaCl, 1 mM DTT, 2 mM MgCl2, 0.1% NP40,
10% glycerol, 1 mM phenylmethanesulphonylfluoride (PMSF), 0.01 mg bovine
serum albumin (BSA), and 1 mM ATP. The products were resolved in 10%
SDS-PAGE.
Hypophosphorylation of GST-ASF/SF2 was carried out by incubating 1.5 ug
GST-ASF/SF2 and 5 ug His-SRPK1(DNS3) in 20 mM Tris-HCl (pH 7.5), 75 mM
NaCl, 1 mM DTT, 2 mM MgCl2, 0.1% NP40, 10% glycerol, 1 mM PMSF, and
0.01 mg BSA and 1 mM ATP for 2 hr at room temperature. Because SRPK1
tends to interact with pASF/SF2, we first removed SRPK1 from GST-pASF/
SF2 using the following strategy. The phosphorylation reaction was mixed
with 15 ml glutathione sepharose resin for 30 min at cold room. Beads were
then washed sequentially with binding buffers (20 mM Tris-HCl [pH 7.5],
75 mM NaCl, 1 mM DTT, 2 mM MgCl2, 0.1% NP40, 10% glycerol, 1 mM
PMSF, and 0.01 mg BSA) containing 2 M, 1 M, 0.5 M, 0.05 M, and 0 M urea.
GST-ASF/SF2 and free GST were subjected to a similar treatment. Bound
proteins were then put into reaction with 2 mg His-CLK1 in a cold room for
1 hr. Unbound proteins were removed by centrifugation and five washing steps
using binding buffer with NP40 decreased to 0.5%. Bound proteins were
separated by SDS-PAGE followed by western blot with anti-His and anti-
GST antibodies.
Crystallization
CLK1 was concentrated to 7 mg/ml in the presence of 10Z-hymenialdisine
(0.5 mM final concentration) and buffered in 50 mM HEPES (pH 7.5),
500 mM NaCl, 5% glycerol, 50 mM L-glutamic acid, 50 mM L-arginine, and
10 mM DTT. Crystals were grown at 4C in 150 nl sitting drops mixing 75 nl
CLK1 with 75 nl of a precipitate solution containing 20% PEG 6K and 0.1 M
bicine (pH 9.0). CLK3 crystals were grown at 4C in 150 nl sitting drops mixing
75 nl CLK3 (11 mg/ml in 50 mM HEPES [pH 7.5], 200 mM NaCl, 10 mM DTT)
with 75 nl of a solution containing 27% PEG 3350, 30 mM ammonium acetate,
and 0.1 M BisTris (pH 5.5).
Structure Determination
Diffraction data were collected on cryocooled crystals (100 K) using the X10SA
beamline at the Swiss Light Source. CLK3 images were indexed and
integrated using MOSFLM (Leslie, 1992), and scaled using SCALA (Evans,
1993) implemented in the CCP4 (CCP4, 1994) suite of programs. The CLK1
data were processed with HKL2000 (Otwinowski and Minor, 1997). The
CLK1 structure was solved using molecular replacement and the program
Phaser (Storoni et al., 2004) using human CDK6 (PDB code 1JOW) as a search
model. CLK1 was used for molecular replacement in the determination of the
CLK3 structure. Restrained refinement with TLS against maximum likelihood
targets was carried out using REFMAC5 (Murshudov et al., 1997).
ACCESSION NUMBERS
Coordinates for the CLK1 and CLK3 structures have been deposited in the
Protein Data Bank under the ID codes 1Z57 and 2EU9, respectively.
SUPPLEMENTAL DATA
The Supplemental Data include one figure and can be found with this article on-
line at http://www.cell.com/structure/supplemental/S0969-2126(09)00078-1.Structure 17, 3ACKNOWLEDGMENTS
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